To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia
Status:
Not yet recruiting
Trial end date:
2023-01-20
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to
evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic
alopecia.